Protocol H8A-MC-LZAX. Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY20624030) Versus Placebo
Aimee Pierce, MD
UC Irvine Campus (UCI MIND Gottschalk Medical Plaza, ICTS in Hewitt Hall, Brain Imaging Center in Irvine Hall).
To evaluate the effectiveness and long-term safety of immunization treatment with solanezumab versus placebo in patients with mild Alzheimer's disease.
Patients with probable Alzheimer's disease at the mild stage.
22 visits over the course of up to 80 weeks total (~ 1.5 years).
You may or may not receive any benefit from being in this study. If you are in the group that receives the study drug solanezumab, and it proves to treat your condition better than placebo, you may benefit from participating in the study, but this cannot be guaranteed. While researchers hope solanezumab will be better than other available treatments, there is no proof of this yet. If you take part in this study, other people with AD may be helped.
You may receive information from physical examinations, laboratory tests, or other testing that is done in this study but these tests may not have any impact on your health.
The information collected from this study may increase knowledge regarding the treatment of Alzheimer’s disease and help people in the future.
You will not be compensated for your participation in this research study. If you have to travel some distance to the study site, a maximum of $40 will be provided for each visit required for the study.
Beatriz Yanez, RN, Clinical Research Nurse and Coordinator